Annual report pursuant to Section 13 and 15(d)

Collaborative Arrangements - Performance Period (Details)

v3.20.4
Collaborative Arrangements - Performance Period (Details)
Dec. 31, 2020
Jun. 30, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Expected timing of satisfaction, period 1 year  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Expected timing of satisfaction, period 1 year  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Expected timing of satisfaction, period 1 year  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Expected timing of satisfaction, period  
Molecular Assemblies, Inc. | Commercialization And Enzyme Supply Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-12-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Expected timing of satisfaction, period   6 months
Molecular Assemblies, Inc. | Minimum | Master Collaboration & Research Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-04-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Expected timing of satisfaction, period   10 months
Molecular Assemblies, Inc. | Maximum | Master Collaboration & Research Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-07-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Expected timing of satisfaction, period   13 months
Novartis | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]    
Expected timing of satisfaction, period 23 months